
Baxter reported $3 billion in Q3 2026 sales, up 5% organically, and raised its full-year guidance for organic sales growth and adjusted earnings. The company is discontinuing cephalosporin antibiotic production at its Illinois plant to simplify manufacturing and address FDA concerns, without causing market shortages. Baxter also retired $864 million in debt, aiming to reduce net leverage to about three times earnings by year-end. Internal efficiency programs continue to drive cost savings and improved margins, supporting long-term performance gains.
Baxter International Inc (BAX) shares are currently priced at USD 26.18 on Pluang, showing a 1.65% increase in the last day. The stock's market cap stands at $13.33 billion as of Nov 19, 2026 03:51 WIB, reflecting steady investor interest amid the company's operational updates.